Franklin Resources Inc. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Franklin Resources Inc. grew its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 7.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,981 shares of the specialty pharmaceutical company’s stock after buying an additional 2,121 shares during the period. Franklin Resources Inc. owned approximately 0.05% of Supernus Pharmaceuticals worth $987,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in SUPN. Armistice Capital LLC grew its position in Supernus Pharmaceuticals by 47.6% in the second quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock worth $141,026,000 after acquiring an additional 1,700,000 shares in the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 100,186.3% in the 2nd quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock worth $36,109,000 after purchasing an additional 1,348,508 shares in the last quarter. American Century Companies Inc. increased its position in shares of Supernus Pharmaceuticals by 369.1% during the 2nd quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company’s stock valued at $13,419,000 after purchasing an additional 394,728 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Supernus Pharmaceuticals by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock valued at $45,077,000 after buying an additional 351,900 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Supernus Pharmaceuticals by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after buying an additional 309,966 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the transaction, the chief executive officer now owns 926,172 shares in the company, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now owns 8,200 shares in the company, valued at approximately $303,236. This trade represents a 64.66 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 154,213 shares of company stock valued at $5,660,180. Company insiders own 9.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $37.18 on Friday. The stock has a market capitalization of $2.05 billion, a P/E ratio of 34.75 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $39.37. The business’s 50 day simple moving average is $35.88 and its two-hundred day simple moving average is $32.53.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. During the same period in the previous year, the firm earned ($0.29) earnings per share. The business’s revenue was up 14.2% compared to the same quarter last year. Sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.